Compare DARE & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DARE | NMTC |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | 24 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 39.5M |
| IPO Year | 2014 | 2010 |
| Metric | DARE | NMTC |
|---|---|---|
| Price | $2.36 | $3.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $10.00 | ★ $11.90 |
| AVG Volume (30 Days) | ★ 769.5K | 31.0K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.43 |
| EPS | ★ N/A | N/A |
| Revenue | $2,807,885.00 | ★ $9,097,692.00 |
| Revenue This Year | $2,115.12 | N/A |
| Revenue Next Year | $122.62 | $31.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 163.47 |
| 52 Week Low | $1.27 | $0.55 |
| 52 Week High | $9.19 | $5.40 |
| Indicator | DARE | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 46.24 |
| Support Level | $1.79 | $0.69 |
| Resistance Level | $2.54 | $4.87 |
| Average True Range (ATR) | 0.35 | 0.37 |
| MACD | -0.07 | -0.21 |
| Stochastic Oscillator | 22.28 | 5.66 |
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.